BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Vertex Pharmaceuticals Incorporated 

Research & Development
275 Armand-Frappier
Laval  Quebec  H7V 4A7  Canada
Phone: 450-978-7700 Fax: 450-978-7972


The Science of Possibility.

Vertex Canada is home to innovators in biopharmaceutical research and development. We employ approximately 60 professionals at our research facility in Laval, Quebec, including approximately 45 scientists focused on drug discovery and development activities.

Vertex’s Canadian team is focused on research activities related to inflammatory bowel diseases (IBD), which include Crohn’s Disease and ulcerative colitis. Vertex Canada features a diverse scientific team covering all of our major disciplines and fosters strong cross-functional teams between departments.

Our workplace reflects the rich multiculturalism of the area, which our employees point to as a key advantage of working here. Scientists and researchers from our Laval location have strong collaborative relationships with academic institutions in the area, as well as with our other Vertex locations worldwide.

As part of Vertex’s global network of science research, the Laval site is positioned to continue its quarter century of Canadian contribution to discovering new possibilities in medicine and advancing Canada’s scientific research workforce.

For more information on Vertex, please visit For information on career opportunities with Vertex Canada, please visit

 Key Statistics

Ownership: Public

Web Site: Vertex (Canada)
Symbol: VRTX

 Company News
Vertex Pharmaceuticals Incorporated (VRTX) To Present At Upcoming Investor Conferences 2/12/2015 7:46:58 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Full-Year And Fourth Quarter 2014 Financial Results And Provides Guidance For 2015 1/29/2015 11:06:46 AM
Vertex Pharmaceuticals Incorporated (VRTX) Outlines 2015 Business Priorities To Support The Development, Approval And Launch Of New Medicines For The Treatment Of People With Cystic Fibrosis 1/12/2015 1:26:41 PM
Vertex Pharmaceuticals Incorporated (VRTX) Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2014 Financial Results 1/7/2015 9:46:41 AM
Royalty Pharma Buys Royalties On Vertex Pharmaceuticals Incorporated (VRTX) Drugs For $3.3 Billion 11/19/2014 5:47:18 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At The Credit Suisse Healthcare Conference On November 11 10/31/2014 8:56:44 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Third Quarter 2014 Financial Results 10/29/2014 8:50:50 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At Morgan Stanley (MST) Global Healthcare Conference On September 10 9/3/2014 1:51:40 PM
Vertex Pharmaceuticals Incorporated (VRTX) Receives European Approval For KALYDECO™ (ivacaftor) In Eight Non-G551D Gating Mutations 8/1/2014 10:27:36 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Second Quarter 2014 Financial Results And Provides Updates On Key Research And Development Programs 7/30/2014 10:41:59 AM